Skip to content

Self-management of Anticoagulation Treatment

Comparison Between Conventional Anticoagulation Treatment and Self-management of Anticoagulation Treatment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02371772
Enrollment
23
Registered
2015-02-26
Start date
2008-08-31
Completion date
2009-09-30
Last updated
2015-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long-term Oral Anticoagulant Therapy

Keywords

Warfarin, Self Care, Conventional care

Brief summary

The aim of the study was to compare self-management of anticoagulant treatment with conventional anticoagulant treatment in Norway.

Detailed description

Patients (n=23) on anticoagulant treatment with warfarin participated in a 27 weeks training program where they learned how to analyse International Normalised Ratio (INR) using the point-of-care instrument CoaguChek® XS and dose warfarin. The patients had to display their skills through a test before considered self-managing. They continued to measure INR weekly for 28 weeks. All INR values during the training program and self-control period were collected. In addition, the patients were told to notify if they had any complications during this period. Ten INR values and complications before enrolment was collected from INR cards and/or their general practioner. The participant filled in a quality of life-questioner at enrolment and after 28 weeks of self-management.

Interventions

OTHERTraining

Patients were trained to monitor INR and dose warfarin

Sponsors

Una Ørvim Sølvik
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* on life-long oral anticoagulation therapy * Live in Bergen municipality * Judged to be qualified for patient self-management anticoagulation treatment by their GP * Motivated to follow the training program

Exclusion criteria

* Drug abuse * Liver disease

Design outcomes

Primary

MeasureTime frame
Change in Time in therapeutic range (TTR)From 39 weeks before enrolment until 28 weeks of self management

Secondary

MeasureTime frame
Change in number of complicationsFrom 39 weeks before enrolment until 28 weeks of self management

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026